Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase II Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced positive top-line data from the TOPAZ Phase II clinical trial evaluating apitegromab in patients with Type 2 and Type 3 SMA.